Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M
Semaglutide: FDA-approved for weight management (2021) and type 2 diabetes Widely available via prescription Available from research peptide suppliers Established insurance coverage pathways Years of post-marketing safety data Cagrilintide: Not FDA-approved (investigational as of March 2026) Phase 3 REDEFINE trials complete with positive results Available from some research peptide suppliers as a research chemical No insurance coverage Limited long-term safety data (68 weeks maximum from trials) Cost Considerations Without FDA approval, cagrilintide has no established retail price
Retatrutide: A Triple Threat in Metabolic Regulation Retatrutide stands as a cutting-edge pharmaceutical peptide, developed by Eli Lilly, designed to address the complex challenges of obesity and type 2 diabetes
They may also recommend supplements or injections